1. Signaling Pathways
  2. Apoptosis
  3. Caspase
  4. Caspase 7 Isoform
  5. Caspase 7 Inhibitor

Caspase 7 Inhibitor

Caspase 7 Inhibitors (8):

Cat. No. Product Name Effect Purity
  • HY-12305
    Q-VD-OPh
    Inhibitor 99.78%
    Q-VD-OPh is an irreversible pan-caspase inhibitor with potent antiapoptotic properties; inhibits caspase 7 with an IC50 of 48 nM and 25-400 nM for other caspases including caspase 1, 3, 8, 9, 10, and 12. Q-VD-OPh can inhibits HIV infection. Q-VD-OPh is able to cross the blood-brain barrier.
  • HY-P1001
    Ac-DEVD-CHO
    Inhibitor 99.94%
    Ac-DEVD-CHO is a specific Caspase-3 inhibitor with a Ki value of 230 pM.
  • HY-P0109A
    Z-FA-FMK
    Inhibitor 99.14%
    Z-FA-FMK ((1S)-Z-FA-FMK) is a potent Cathepsin B and L inhibitor. Z-FA-FMK blocks the induction of DEVDase activity, DNA fragmentation, and externalization of phosphatidylserine by selective synthetic retinoid-related molecules (RRMs). Z-FA-FMK inhibits apoptosis. Z-FA-FMK inhibits caspase activity and selectively inhibits recombinant effector caspases 2, -3, -6, and -7. Z-FA-FMK is a viral inhibitor. Z-FA-FMK inhibits reovirus replication in a susceptible host.
  • HY-136975
    Caspase-3-IN-1
    Inhibitor
    Caspase-3-IN-1 (compound 11b) is a potent Caspase-3 inhibitor, with an IC50 of 14.5 nM.
  • HY-108312
    AC-VEID-CHO
    Inhibitor
    AC-VEID-CHO is a peptide-derived caspase inhibitor and has potency of inhibition for Caspase-6, Caspase-3 and Caspase-7 with IC50 values of 16.2 nM, 13.6 nM and 162.1 nM, respectively. AC-VEID-CHO also inhibits VEIDase activity an IC50 value of 0.49 µM. AC-VEID-CHO can be used for the research of neurodegenerative conditions including Alzheimer’s and Huntington’s disease.
  • HY-108312A
    AC-VEID-CHO TFA
    Inhibitor 98.7%
    AC-VEID-CHO (TFA) is a peptide-derived caspase inhibitor and has potency of inhibition for Caspase-6, Caspase-3 and Caspase-7 with IC50 values of 16.2 nM, 13.6 nM and 162.1 nM, respectively. AC-VEID-CHO (TFA) can be used for the research of neurodegenerative conditions including Alzheimer’s and Huntington’s disease.
  • HY-157088
    C105SR
    Inhibitor 98.86%
    C105SR is a cyclophilin D (CypD) inhibitor targeting to peptidyl-prolylcis-trans isomerase (PPIase). C105SR inhibits mitochondrial permeability transition opening (mPTP) with an IC 50 of 5 nM. C105SR inhibits hypoxia and reoxygenation inudced hepatocyte apoptosis and increases the level of calcium retention capacity (CRC). C105SR exhibits hepaprotective effect in ischaemia-reperfusion injury (IRI) mouse model.
  • HY-137038
    N-a-Tosyl-L-lysinyl-chloromethylketone hydrochloride
    Inhibitor
    N-a-Tosyl-L-lysinyl-chloromethylketone hydrochloride (TLCK hydrochloride) is an irreversible inhibitor for serine protease, which inhibits trypsin and trypsin-like protease by alkylating histidine residues in their active site. N-a-Tosyl-L-lysinyl-chloromethylketone hydrochloride inhibits caspase-3, caspase-6 and caspase-7, with IC50s of 12.0, 54.5 and 19.3 μM, respectively. N-a-Tosyl-L-lysinyl-chloromethylketone hydrochloride induces apoptosis in cell HL-60, and inhibits the decrease in mitochondrial transmembrane potential during apoptosis.